Sun Pharma Advanced Research Company Limited — PPTs, 08-01-2026: Investor Presentation

SPARC, an R&D focused pharma company, is dedicated to developing innovative new medicines and differentiated formulations. Its core strength lies in a robust and diverse pipeline of drugs targeting various therapeutic areas.

The company's strategy hinges on its deep R&D capabilities and strategic partnerships, notably with Sun Pharma for commercialization, which are key to future growth.

SPARC has successfully secured US approvals for APO-Go (Parkinson's) and Elepsia (epilepsy), both now commercialized by Sun Pharma. Further, its Pramipexole (SAR-318) for Parkinson's is in advanced Phase III trials. Several other promising candidates, including SAR-2245 (Psoriasis) and SAR-1008 (Atopic Dermatitis), are progressing through Phase II.

Management's outlook is firmly rooted in continuously advancing this innovative drug pipeline. This broad portfolio across neurology, dermatology, and ophthalmology underpins SPARC's long-term value creation by bringing new treatments to market.